Linagliptin for type 2 diabetes is safe to use

被引：0
|
作者：
Pettersen, Petter Morten
机构：
来源：
TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING | 2019年 / 139卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [41] Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus
    Yu. S. Gavrilova
    N. P. Bgatova
    V. V. Klimontov
    I. Yu. Ischenko
    S. V. Michurina
    N. E. Myakina
    E. L. Zavyalov
    Bulletin of Experimental Biology and Medicine, 2016, 161 : 501 - 504
  • [42] Efficacy and Safety of Linagliptin in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
    Taskinen, Marja-Riitta
    Rosenstock, Julio
    Tamminen, Ilkka
    Kubiak, Rene
    Patel, Sanjay
    Dugi, Klaus A.
    Woerle, Hans-Juergen
    DIABETES, 2010, 59 : A158 - A158
  • [43] Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Poor Glycemic Control
    Del Prato, Stefano
    Taskinen, Marja-Riitta
    Owens, David
    Von Eynatten, Maximillian
    Emser, Angela
    Patel, Sanjay
    Woerle, Hans J.
    DIABETES, 2011, 60 : A293 - A293
  • [44] Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
    Gallwitz, Baptist
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 1 - 9
  • [45] Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
    Triplitt, C.
    Solis-Herrera, C.
    Cersosimo, E.
    Abdul-Ghani, M.
    Defronzo, Ralph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2819 - 2833
  • [46] Efficacy and Safety of Linagliptin in Elderly Patients (≥ 70 Years) With Type 2 Diabetes
    Barnett, Anthony
    Huisman, Holger
    Jones, Russell
    Von Eynatten, Maximilian
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A260 - A261
  • [47] Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus
    Gavrilova, Yu. S.
    Bgatova, N. P.
    Klimontov, V. V.
    Ischenko, I. Yu.
    Michurina, S. V.
    Myakina, N. E.
    Zavyalov, E. L.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 161 (04) : 501 - 504
  • [48] The safety and efficacy of Linagliptin in patients with type 2 diabetes with severe renal impairment
    Sloan, L.
    Newman, J.
    Sauce, C.
    von Eynatten, M.
    Patel, S.
    Woerle, H. J.
    Katsadze, V.
    DIABETES & METABOLISM, 2012, 38 : A102 - A103
  • [49] Linagliptin-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
    Gallwitz, Baptist
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2012, 5 : 1 - 11
  • [50] Impact of linagliptin therapy in patients with Type 2 diabetes and suboptimal glycaemic control
    Holland, A. L.
    Gururaj, S.
    Lawrence, I.
    DIABETIC MEDICINE, 2014, 31 : 182 - 183
12345